Skye Bioscience Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Skye Bioscience diminuiranno a una percentuale pari a 36.1% all'anno. Si prevede che l'EPS diminuirà a una percentuale pari a 28.7% all'anno.

Informazioni chiave

-36.1%

Tasso di crescita degli utili

-28.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	08 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:SKYE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-52	-47	-33	4
12/31/2025	N/A	-41	-21	-26	6
12/31/2024	N/A	-29	-25	-22	6
9/30/2024	N/A	-21	-22	-21	N/A
6/30/2024	N/A	-42	-20	-20	N/A
3/31/2024	N/A	-37	-15	-15	N/A
12/31/2023	N/A	-38	-14	-14	N/A
9/30/2023	N/A	-43	-15	-15	N/A
6/30/2023	N/A	-21	-13	-13	N/A
3/31/2023	N/A	-22	-14	-14	N/A
12/31/2022	N/A	-19	-13	-13	N/A
9/30/2022	N/A	-12	-10	-10	N/A
6/30/2022	N/A	-11	-9	-9	N/A
3/31/2022	N/A	-9	-8	-8	N/A
12/31/2021	N/A	-9	-7	-6	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-7	-7	-7	N/A
3/31/2021	N/A	-6	-6	-6	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	0	-6	-6	N/A
6/30/2020	N/A	-4	-5	-5	N/A
3/31/2020	N/A	13	-6	-6	N/A
12/31/2019	N/A	1	-6	-6	N/A
9/30/2019	N/A	-10	-6	-6	N/A
6/30/2019	N/A	-7	-5	-5	N/A
3/31/2019	N/A	-26	-4	-4	N/A
12/31/2018	N/A	-19	-4	-4	N/A
9/30/2018	N/A	-14	-5	-5	N/A
6/30/2018	N/A	-12	N/A	-4	N/A
3/31/2018	N/A	-10	N/A	-4	N/A
12/31/2017	N/A	-4	N/A	-3	N/A
9/30/2017	N/A	-5	N/A	-2	N/A
6/30/2017	N/A	-5	N/A	-2	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-4	N/A	-4	N/A
9/30/2016	N/A	-3	N/A	-4	N/A
6/30/2016	N/A	-3	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-4	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-6	N/A	-3	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-1	N/A	-1	N/A
6/30/2014	N/A	0	N/A	0	N/A
3/31/2014	N/A	0	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che SKYE rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che SKYE rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che SKYE rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SKYE cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Si prevede che SKYE non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SKYE è previsto essere elevato tra 3 anni

Skye Bioscience Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita